| INTRODUCTION
Although traditionally misconceived as a "man's disease," atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death among women. With an increase in awareness and appropriate therapies, ASCVD-associated deaths among both genders >65 years of age in the United States have declined. 1 However, there has been an increase in the average annual rate of death from coronary heart disease (CHD) among young women aged 35 to 54 years, whereas there has been a decrease in the annual rate of death in men of the same age group. 1 The gender differences in ASCVD risk profiles ( Figure 1 ) are, therefore, important to understand to reduce this burden on women. These differences range from varying sex-chromosome-related gene expression to differing behaviors, lifestyles, environment, and expectations arising from sociocultural practices according to gender. Based on these differences, the American Heart Association (AHA) published guidelines for the prevention of cardiovascular (CV) disease in women in 2011. 2 A high-level overview of these guidelines in conjunction with additional evidence on prevention of ASCVD that has emerged since 2011 will be discussed to provide a comprehensive approach to risk assessment and stratification of ASCVD in women, as well as a review of effective preventive measures.
| RISK FACTORS FOR CV DISEASE UNIQUE TO WOMEN

| Hypertensive disorders of pregnancy
Although gestational hypertension and preeclampsia resolve within 3 months postpartum, they are associated with residual vascular dysfunction and increased ASCVD risk in women, recognized as a major risk factor by the 2011 AHA guidelines. 2 The placenta is hypoperfused, and inflammatory cytokines and antiangiogenic proteins are released in preeclampsia, leading to systemic endothelial dysfunction, vasoconstriction, and reduced perfusion to various organ systems. 10 There was no difference in incidence of CHD events between the estrogen-progestin and placebo group in the HERS trial, despite a decrease in lowdensity lipoprotein (LDL) and an increase in high-density lipoprotein (HDL) in the experimental group. 11 Based on these results, the current recommendation of the US Preventive Services Task Force is against the use of combined estrogen and progestin or estrogen alone for prevention of ASCVD in menopausal women.
| RISK FACTORS FOR CV DISEASE THAT DISPROPORTIONATELY AFFECT WOMEN
| Autoimmune disorders
Systemic autoimmune disorders occur predominantly in women, which predisposes them to chronic inflammation, endothelial dysfunction, and accelerated atherosclerosis. Women with systemic lupus erythematosus (SLE) between the ages of 35 and 44 years were found to be more likely to have an MI, compared to their age- 21.6-98.5). 12 
| GENDER DISPARITIES IN TRADITIONAL ASCVD RISK FACTORS
In both women and men, the traditional risk factors, including hypertension, dyslipidemia, diabetes mellitus, and smoking, are strongly associated with ASCVD risk. However, there are sex differences in prevalence and magnitude of associated ASCVD risk (Table 1) . Obesity and sedentary behavior are more common in women. 13 Weight gain during pregnancy may contribute to the sex difference in the prevalence of obesity, whereas barriers to physical activity (PA) are different in women than in men, in part because of traditional female gender roles such as caretaker responsibilities. 14 Smoking is more prevalent in men (20.5%) than in women (15.9%), 1 but the relative risk of CHD associated with smoking is 25% greater in women than in men, even after adjustment for other CV risk factors. 15 The reason for this discrepancy is not known. Differences in nicotine metabolism and smoking behavior have been suggested as possible mechanisms.
Diabetic women are more likely to both develop and die from CVD than their male counterparts. 16 In fact, impaired fasting glucose alone causes increased CHD risk in women to a similar extent as diabetes does, an association not observed in men. 17 Despite this, diabetic women with CHD are less likely to be treated with aspirin and less likely to have their hyperlipidemia and hypertension optimized than similarly affected men. 18 Women are also less likely to have their hypertension controlled compared to men (54% vs 58.7%, respectively; P < 0.02), especially with older age (53.4% vs 63.2% for ages 65-80 years; P < 0.005). 19 
| GENDER DISPARITIES IN NONTRADITIONAL ASCVD RISK FACTORS
| Depression
Depression is associated with increased mortality following MI and moderately increased risk for future major adverse cardiac events. 20 In the large, international case-control study INTERHEART 
| Social determinants of health
Psychosocial stressors, such as perceived stress, life events, have been associated with increased ASCVD risk. 21 Women are especially vulnerable, as they represent 60% of the world's poor and 66% of illiterate adults, 23 given the differential distribution of income in men vs women. The WISE (Women's Ischemia Syndrome Evaluation) study showed that income was a significant predictor of CV death or MI, after adjusting for angiographic coronary disease, chest pain symptoms, and traditional risk factors. 24 
| Risk markers for atherosclerosis
The 2013 ACC/AHA guidelines recommend addressing novel markers to enhance risk classification in individuals at intermediate risk. 25 Inflammatory markers, such as high-sensitivity C-reactive protein Statins are recommended for primary prevention in women according to the 2013 ACC guidelines, although randomized trial evidence is limited.
Statins are effective for secondary prevention in both women and men.
Obesity, physical inactivity
In the United States, obesity is more common in women than in men (35.5% vs 33.8%).
For weight loss, or sustaining weight loss, women must exercise a minimum of 60 to 90 min of at least moderateintensity on most and preferably all days of the week.
Obesity poses a greater risk of CHD in women.
Smoking
There is 25% greater relative risk of CHD with smoking in women than in men.
Women should be advised not to smoke and to avoid secondhand smoke.
Counseling, nicotine replacement, and medical and/or behavioral therapy should be provided.
Abbreviations: ACC, American College of Cardiology; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CHD, coronary heart disease; CVD, cardiovascular disease; DM, diabetes mellitus; JNC8, 8th Joint National Committee; PAR, population-attributable risk.
(hsCRP), are thought to be subclinical markers associated with increased CV risk independent of a woman's lipid profile. 26 hsCRP is the most extensively examined of the novel markers addressing CV
risk. In the JUPITER (Justification for the Use of Statins in Prevention:
An Intervention Trial Evaluating Rosuvastatin) trial, asymptomatic women ≥60 years old and men ≥50 years old with elevated hsCRP (≥2 mg/L), low LDL levels (<130 mg/dL), and triglyceride levels <500 mg/dL were randomized to receive statin or placebo therapy.
In those treated with statin therapy, incident ASCVD was reduced by 44% and all-cause mortality by 20%. 26 The coronary artery calcium (CAC) score was developed as a noninvasive marker for vascular disease. Calcification of the coronary arteries is measured in Hounsfield units in gated computed tomography imaging, and is converted to an Agatston score (area × density 7 | PREVENTIVE MEASURES
| Lifestyle modifications
The AHA/ACC recommends all adults consume a high intake of vegetables, fruits, and whole grains, as well as low-fat dairy products, poultry, fish, legumes, nontropical vegetable oils, and nuts. Three to 4 sessions per week of aerobic PA lasting an average of 40 min, at a moderate to vigorous intensity, for all adults is also recommended.
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Women may benefit more from PA than men, as the median ASCVD risk reduction associated with PA between most active women and least active women is 40%, whereas in men it is 30%. 13 Therefore, 
| Aspirin
The Women's Health Study sought to evaluate the use of aspirin for primary prevention of ASCVD. 31 Of the 40 000 healthy women, those who received 100 mg of aspirin every other day experienced a reduction in the risk of total strokes and ischemic strokes, with no difference in the risk of MI or death from CV events during a followup period of 10 years. However, women ≥65 years old exhibited the most consistent benefit of aspirin, with a significantly reduced risk of both MI (RR: 0.66; 95% CI: 0.44-0.97; P = 0.04) and ischemic stroke (RR: 0.7; 95% CI: 0.49-1; P = 0.05) when compared to placebos ( Table 2 ). The Hypertension Optimal Treatment study 32 had similar results, but the mechanisms remain unclear. For primary prevention, lipid lowering did not affect total or CHD mortality or major cardiovascular events.
Abbreviations: CHD, coronary heart disease; CI, confidence interval; CV, cardiovascular; CVD, cardiovascular disease; HR, hazard ratio; MI, myocardial infarction; RR, relative risk.
| Statins
The Atherosclerosis Risk in Communities Study showed that elevated LDL and low HDL are independent risk factors for CHD in women, as are elevated triglyceride levels, which were not shown to have a similar association to CHD in men; these risk factors provided a larger relative risk of CHD in women than men. 33 However, in primary prevention trials, lipid-lowering medications did not reduce total mortality, CHD mortality, MI, revascularization, or CHD events in women, despite lowering of cholesterol in both sexes (Table 2) . 34 The wider confidence intervals of these aforementioned endpoints in women are likely secondary to the overall lower incidence of CHD in women
and their under-representation in these trials. With a large number of female participants (38.2%), the JUPITER trial concluded that women without overt dyslipidemia with increased hsCRP experienced a greater reduction in major adverse cardiac events than similarly affected men when placed on high-intensity rosuvastatin ( Table 2) . 35 A 2015 meta-analysis of 6 clinical trials, however, showed no significant difference in statin-related ASCVD benefits between the sexes. 36 Given its lack of differing gender recommendations, the current 2013 ACC/AHA guidelines of treatment with statins 37 should be considered for female patients, despite the existing, equivocal data on statins' primary prevention benefits in women.
| Anticoagulation
Men have a greater risk of developing atrial fibrillation, but female gender is an independent risk for stroke in patients with atrial fibrilla- 
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